Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.81 USD
-0.08 (-8.76%)
Updated May 13, 2024 04:00 PM ET
After-Market: $0.81 0.00 (-0.25%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 81 - 94 ( 94 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Transfer of Coverage; Maintain Buy and $12PT
Provider: Roth Capital Partners, Inc.
Analyst: ISAACSON J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Out With the Old, in With the New; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Aptevo Therapeutics Inc.
Industry: Unclassified
Company: Aptevo Therapeutics Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptevo Therapeutics Inc.
Industry: Unclassified
Healthcare - ORD-ARN-JFK: Crossing Our Onco Radar
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Aptevo Therapeutics Inc.
Industry: Unclassified
Dissecting Recent Progress and Value; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Aptevo Therapeutics Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptevo Therapeutics Inc.
Industry: Unclassified
Company: Aptevo Therapeutics Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptevo Therapeutics Inc.
Industry: Unclassified
An Eclectic Pipeline Trading at Cash; Initiating with Buy and $12 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J